Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

UNBELIEVABLE: Innate pharma q1 earnings call highlights - Caught on Camera

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.

Chief Executive Officer Jonathan Dickinson said the company is continuing to execute “with discipline” and pointed to several expected catalysts in the second half of 2026, including the planned initiation of a confirmatory Phase 3 trial for lacutamab and a Phase 3 readout for monalizumab. He also said the company ended the quarter with a cash position of EUR 25.4 million as of March 31, 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.